Increased bladder CA risk in type 2 diabetes due to bias

This article originally appeared here.
Share this content:
Detection Bias May Explain Raised Bladder CA Risk in T2DM
Detection Bias May Explain Raised Bladder CA Risk in T2DM

(HealthDay News) -- Early detection bias may explain the pattern of increased bladder cancer risk previously reported in patients with type 2 diabetes, according to a study published online Aug. 29 in Diabetes Care.

Isabelle N. Colmers, from the University of Alberta in Edmonton, Canada, and colleagues used linked administrative databases (1996 to 2006) to create a cohort of 185,100 adults from British Columbia, Canada, with incident type 2 diabetes, who were age-, sex-, and index date-matched to individuals without diabetes in a 1:1 ratio. During annual time windows following the index date, the incidence rates and hazard ratios for bladder cancer were calculated.

During a median follow-up of four years, the researchers found that within the study population (54 percent men; average age, 60.7 years) 1,171 new bladder cancer cases were diagnosed. Bladder cancer incidence in the diabetes cohort was 85.3 per 100,000 person-years in the first year after diabetes diagnosis, compared with 66.1 in the control cohort (adjusted hazard ratio, 1.30; P = 0.03). The increased bladder cancer risk seen in the first year was limited to those with the fewest physician visits two years prior to the index date (≤12 visits, adjusted hazard ratio, 2.14; P = 0.003). Type 2 diabetes was not associated with bladder cancer after the first year.

"The results suggest that early detection bias may account for an overestimation in previously reported increased risks of bladder cancer associated with type 2 diabetes," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs